Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Policy / Regulatory

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Drug

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Fineline Cube Mar 18, 2024

Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...

Company Deals

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Fineline Cube Mar 18, 2024

Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...

Company Deals

CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development

Fineline Cube Mar 18, 2024

CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...

Company Drug

Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer

Fineline Cube Mar 18, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...

Company Drug

Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment

Fineline Cube Mar 18, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...

Company Drug

Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH

Fineline Cube Mar 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study

Fineline Cube Mar 18, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company

Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth

Fineline Cube Mar 18, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...

Company Drug

Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market

Fineline Cube Mar 18, 2024

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...

Company Drug

FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma

Fineline Cube Mar 18, 2024

An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...

Company Drug

Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR

Fineline Cube Mar 15, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...

Company Deals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline

Fineline Cube Mar 15, 2024

AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...

Company Drug

KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma

Fineline Cube Mar 15, 2024

Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...

Company Deals

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Fineline Cube Mar 15, 2024

Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...

Company Drug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

Fineline Cube Mar 15, 2024

Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...

Company Drug

Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults

Fineline Cube Mar 15, 2024

The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...

Deals Hospital

Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia

Fineline Cube Mar 15, 2024

Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...

Legal / IP

CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...

Posts pagination

1 … 343 344 345 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.